Navigation Links
WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
Date:1/8/2016

SHANGHAI, Jan. 8, 2016 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, today congratulated Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), a well-established Chinese pharmaceutical company that is a subsidiary of Sino Biopharmaceutical Ltd., and Janssen Pharmaceuticals Inc. (Janssen), a leading global pharmaceutical company, for having reached an exclusive license agreement. Under this agreement, CTTQ grants Janssen rights to develop and commercialize an undisclosed immuno-modulating agent to treat chronic hepatitis B virus (HBV) infection globally outside China. Both CTTQ and Janssen are long-time collaboration partners of WuXi. In 2013, CTTQ signed a contract with WuXi to discover anti-HBV small-molecule drugs. WuXi provided end-to-end integrated research services on the compound that is the subject of this license agreement.

Hepatitis B is a serious and potentially fatal infectious disease afflicting more than 350 million patients worldwide. China has the world's largest hepatitis B patient population. Currently there is no cure for the disease, and effective new drugs are urgently needed.

"We congratulate CTTQ and Janssen on this important agreement," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "WuXi is proud to have played a part in this collaboration to bring an innovative drug candidate closer to hepatitis B patients in China and around the world."

About WuXi AppTec

WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.

For more information, please contact:
Aaron Shi
Director of Corporate Communications
+86-21 5046-4362
aaron_shi@wuxiapptec.com


'/>"/>
SOURCE WuXi AppTec
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. WuXi AppTec Denies Issuing Press Release Regarding Great Basin Scientific
2. Med Data Quest Tackles Oncology Informatics Challenges with WuXi AppTec
3. Nobel Prize Laureate Professor Barry Sharpless Visits WuXi AppTec Headquarters in Shanghai
4. WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax
5. WuXi AppTec Successfully Completes Its First 2000L Disposable Bioreactor Run Using an NS0 Cell Line, Marking an Industry Milestone
6. National Photonics Initiative Congratulates Industry Partner Hamamatsu on Contributions to Nobel Prize-Winning Research
7. North American Cannabis Holdings Congratulates JV Partner NaturesComfortMeds on Award of Two US Patents
8. OTC Markets Group Congratulates Aethlon Medical on NASDAQ Listing
9. OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing
10. Kids v Cancer Congratulates United Therapeutics on Receiving Priority Review Voucher Through the Creating Hope Act
11. WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):